The FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study.
News|Articles|June 5, 2026
Pediatric clinical trial update: May 2026
Author(s)Morgan Ebert, Executive Editor
Fact checked by: Benjamin P. Saylor
A look back at the latest clinical trial updates for the pediatric population during May 2026.
Advertisement
Advertisement
May brought a steady stream of clinical trial developments with potential implications for pediatric care, spanning infectious diseases, neurology, endocrinology, gastroenterology, and rare diseases. From new data on antiviral prevention strategies and emerging therapies for Tourette syndrome to advances in diabetes management and treatments for pediatric cardiomyopathy, investigators reported findings that may help shape future clinical practice and regulatory decisions.
Related to this article
Tezepelumab produced histologic remission in up to 68.9% of patients aged 12+ with EoE vs 3.5% with placebo at week 24, sustained to week 52.
In phase 3 SHINE-2, 50% of mirikizumab induction responders aged 6 to 17 with moderate to severe UC were in clinical remission at week 52.
Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.
Diana F. Clarke, PharmD, explains how IMPAACT 2023 supported dolutegravir from birth, plus dosing tips and open questions for preterm infants.
New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.
Advertisement
Advertisement